

20 November 2015

CMA Acknowledges Government's Focus on Reducing Red Tape

Mr Carl Gibson, chief executive officer of Complementary Medicines Australia (CMA) has today acknowledged publication of the report by the Government's Expert Review of Medicines and Medical Devices Regulation regarding the regulatory framework for complementary medicines and the advertising of therapeutic goods.

"This is a once in a generation opportunity to shape the regulatory framework for the future in line with the Government's *Industry, Innovation and Competitiveness Agenda* – and to find the required balance between a regulatory environment that protects consumers without unduly restricting the ability for Australian businesses to compete in an increasingly globalized environment."

"CMA supports the Government's stated focus of better aligning regulatory protections with risks and to ease the regulatory requirements where they do little to improve consumer protections and are a barrier to business and innovation."

"Australian complementary medicines are manufactured and regulated to the highest standards. The aim of the Review is to identify areas of unnecessary or ineffective regulation that could be removed or streamlined without undermining the safety or quality of therapeutic goods, taking into account how Australia can continue to be positioned to respond effectively to global trends."

"The complementary medicines industry looks forward to engaging further with the regulator and government to collaboratively work towards an appropriate and 'light-touch' regulatory framework for complementary medicines," said Mr Gibson.

ENDS

For Media Interviews or Further Information Contact:

CMA, Chief Executive

Carl Gibson

+61 457 028 974